Citations

Clear

4207 citation(s) found for "Chen, Yu".

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update
Chen, Alice P. , Rosenberger, Christina L. , Moore, Nancy, Foster, Jared C. , Naqash, Abdul Rafeh , Sharon, Elad , Coyne, Geraldine O’Sullivan , Schwartz, Gary K. , Riedel, Richard F. , Glod, John, Hu, James , Read, William L., Merriam, Priscilla , Deshpande, Hari A., Ladle, Brian H. , Okuno, Scott H. , Beck, Jill C., Chen, J Y, Ferry‐Galow, Katherine V., Fino, Kristin, Wilsker, Deborah, Begum, Asma , Parchment, Ralph E. , Doroshow, James H. , O'Sullivan Coyne, Geraldine , Conley, Anthony P , Burgess, Melissa A , Davis, Elizabeth J , Merriam, Priscilla , Ladle, Brian H , Okuno, Scott , Chen, James L , Ferry-Galow, Katherine V , Miller, Brandon L , Wilsker, Deborah F , Doroshow, James H , Riedel, Richard F , Sharon, Elad , Naqash, Abdul Rafeh , Schwartz, Gary K , Moore, Nancy, Glod, John , Conley, Anthony P. , Read, William, Burgess, Melissa , Davis, Elizabeth J. , Deshpande, Hari A.

Mayo Clinic

Journal of Clinical Oncology | April 18, 2026 | Volume: 44 | Issue: 16 | Pages: 1490-1497

10.1200/jco-25-02811 | PMID 41999612 Get It

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684 ). Here, we report on three additional years of observation. Fifty-three patients with ASPS received atezolizumab. Median duration of response increased to 37.0 months. Objective response rate (ORR) and median progression-free survival (mPFS) remained essentially as previously reported (35.8% [95% CI, 23.1 to 50.2] and 20.8 months [IQR, 7.6-not reached], respectively). ASPSCR1::TFE3 fusion type was determined for 47/53 patients; ORR and mPFS were higher among the 41 patients expressing type 1 (43.9% [95% CI, 28.5 to 60.2] and 28.3 months [IQR, 9.2-not reached], respectively) than the six patients expressing type 2 (0% [95% CI, 0 to 45.9] and 7.5 months [IQR, 3.9-not reached], respectively, PFS HR, 3.2 [95% CI, 1.01 to 10.2]). Eleven patients chose a per-protocol drug holiday (range, 3.5-26.4 months) after ≥2 years of treatment; two experienced disease progression during the holiday. Nine eligible patients elected to receive bevacizumab plus atezolizumab after progressing on monotherapy; ORR was 0% and mPFS was 18.5 months (IQR, 7.9-21.1) in this small cohort. Long-term results support using atezolizumab to treat ASPS, even for several years; a drug holiday with careful monitoring may be an option for some patients.
Abstract LB390: Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium
Zhang, Yifan , Cheng, Shuyan , Boddicker, Nicholas, Lebo, Matthew , Berry, Alexander S. , Hausler, Ryan , Desai, Heena, Rodriguez, Alex A , Hill, Andrew, Sheng, Xin, Gundell, Susan, Cicek, Mine S., Gignoux, Chris , Garraway, Isla P. , Pasaniuc, Bogdan, Oetjens, Matt, Kibel, Adam S., Kote-Jarai, Zsofia, Couch, Fergus J., Darst, Burcu F., Conti, David V., Haiman, Christopher A., Chen, F Z, Conti, David V. , Conti, David V , Boddicker, Nicholas , Haas, Roni , Dadaev, Tokhir , Desai, Heena , Madduri, Ravi , Sheng, Xin , Lilja, Hans , Melander, Olle , Paşaniuc, Bogdan , Boutros, Paul C. , Oetjens, Matthew T. , Kibel, Adam S. , Klein, Robert J. , Kote‐Jarai, Zsofia , Couch, Fergus J. , Maxwell, Kara N. , Darst, Burcu F. , Haiman, Christopher A.

Mayo Clinic

Cancer Research | April 17, 2026 | Volume: 86 | Issue: 8_Supplement | Pages: LB390-LB390

10.1158/1538-7445.am2026-lb390 Get It

Abstract Inherited susceptibility plays a critical role in prostate cancer (PCa) risk. Using large biobank and case-control datasets, we evaluated the contribution of both common variants and rare germline pathogenic variants (PVs) to overall PCa risk. The Prostate Cancer Exome Sequencing Consortium currently includes 427,388 male participants (51,452 PCa cases and 375,936 controls) with whole-exome sequencing data from ten biobanks and studies: UK Biobank (14,669 cases/195,600 controls), All of Us Research Program (7,577/75,226), African Ancestry Prostate Cancer Consortium (7,176/4,675), Mayo Clinic Biobank (6,031/15,084), Mass General Brigham Biobank (3,393/14,095), Geisinger’s MyCode Community Health Initiative (3,026/15,130), UCLA ATLAS Precision Medicine Biobank (2,850/16,904), Penn Medicine Biobank (2,598/16,255), Colorado Center for Personalized Medicine (2,269/13,399), and Malmo Diet and Cancer (1,863/9,568). Based on self-reported race/ethnicity and estimated genetic ancestry, the cases comprise approximately 79% European, 18% African, and 3% other ancestry populations. Single-variant association analyses tested all variants on chromosomes 1-22 and X with a minor allele count ≥ 5. In gene-based analyses, PVs were defined as rare variants (minor allele frequency [MAF] < 1% in controls) that had either a Variant Effect Predictor (VEP) impact score of “high” or a pathogenic or likely pathogenic ClinVar classification. Associations were estimated using Firth logistic regression, adjusting for age and the top ten genetic principal components. Results from individual studies were combined using fixed-effect meta-analysis. In single-variant association analyses, 496 variants reached genome-wide significance (p<5×10-8; MAF>0.02%). Among these, 458 (92%) variants mapped to previously known risk regions, including three rare PVs in HOXB13 (rs138213197), CHEK2 (rs555607708), and FAM111A (rs533676902). Characterization of the remaining 38 variants is ongoing. Gene-based analyses identified significant associations (p<2.4×10-6) for eight genes: HOXB13 (OR=3.7, 95% CI=3.3-4.2), BRCA2 (OR=2.0, 95% CI=1.7-2.3), CHEK2 (OR=1.6, 95% CI=1.5-1.8), ATM (OR=1.6, 95% CI=1.4-1.9), FAM111A (OR=1.4, 95% CI=1.3-1.5), BIK (OR=1.4, 95% CI=1.2-1.6), SAMHD1 (OR=2.1, 95% CI=1.6-2.7), and SMOC2 (OR=3.2, 95% CI=2.0-5.1). All genes except SMOC2 have been previously implicated in PCa susceptibility. Among cancer predisposition and DNA repair genes, nominal associations were also observed for XRCC2 (OR=1.6, 95% CIs=1.2-2.3) and BRCA1 (OR=1.2, 95% CI=1.0-1.4), whereas the association was not significant for PALB2 (OR=1.2, 95% CI=0.9-1.5). These findings reinforce the role of rare germline PVs, particularly in cancer predisposition and DNA repair genes, in PCa susceptibility. As additional studies are incorporated into the Consortium, we expect this work to provide a more comprehensive characterization of the genetic architecture of PCa. Citation Format: Yifan Zhang, Shuyan Cheng, Nicholas Boddicker, Matthew Lebo, Alexander S. Berry, Roni Haas, Ryan Hausler, Tokhir Dadaev, Heena Desai, Alex A. Rodriguez, Ravi K. Madduri, Andrew Hill, Xin Sheng, Susan M. Gundell, Mine Cicek, Penn Medicine Biobank, Olle Melander, Chris R. Gignoux, Isla P. Garraway, Bogdan Pasaniuc, Paul C. Boutros, Matt Oetjens, Adam S. Kibel, Robert J. Klein, Zsofia Kote-Jarai, Fergus J. Couch, Kara N. Maxwell, Burcu F. Darst, David V. Conti, Christopher A. Haiman, Fei Chen. Genetic risk of prostate cancer: Insights from the Prostate Cancer Sequencing Consortium [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(8_Suppl):Abstract nr LB390.
A Retrieval-Based Approach for Automatic Interpretation of Multi-Analyte Laboratory Profiles
Khandelwal, Sarthak, Leger, Rachel, Navitskas, Serena, Pruthi, Rajiv, Chen, Dong , Tavolara, Thomas E, Chen, Dong , Tavolara, Thomas Erol , Leger, Rachel, Navitskas, Serena D., Pruthi, Rajiv K. , Seheult, Jansen N.

Mayo Clinic

The Journal of Applied Laboratory Medicine | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jalm/jfag063 | PMID 42189159 Get It

Abstract Background Interpretation of multi-analyte laboratory profiles, such as lupus anticoagulant (LAC) testing, requires integration of numerous test results and clinical information. However, this process is time-consuming, requires domain knowledge, and has limited scalability. Given that rule-based systems are rigid and difficult to maintain and large language models pose risks of “hallucinations,” we developed and evaluated a novel retrieval-based approach to automate LAC profile interpretation to improve efficiency while maintaining fidelity and reliability for clinical use. Methods Our method processes laboratory values through ensemble random forest (RF) models to retrieve the most similar expert interpretation from a curated database of 347 previously interpreted LAC profiles. The system's performance was assessed through technical accuracy metrics, a work flow efficiency timing study, and expert review of interpretation accuracy for held-out cases. Results Technical validation demonstrated high accuracy in retrieving correct interpretative elements (median: 93% accuracy, interquartile range [IQR]: 67% to 100%). Retrieval accuracy was highly correlated with the prevalence of a given element (ρ = 0.8307). In a timing study of 93 consecutive LAC profiles, ensemble-assisted interpretation achieved a median time of 22 s per report (IQR: 16 s to 31 s), representing a 78.6% total reduction compared to manual interpretation (median: 118 s, IQR: 96 s to 172 s; t = 18.61, P < 0.001). Furthermore, 92.5% of AI-assisted interpretations were completed within 60 s, exceeding the target of 85%. Expert review confirmed 100% concordance for LAC presence/absence. Conclusions The proposed approach significantly improves efficiency of complex laboratory interpretation for LAC profiles, while maintaining consistency and high fidelity. Future studies will explore the method’s inherent extensibility to the interpretation of other multi-analyte laboratory profiles.
International Forum on Visceral Myopathy 2024: Advances in the Knowledge of the Disease
Barbara, Pascal de Santa , Lorenzo, Carlo Di, Alves, Maria M. , Beyder, Arthur, Borrelli, Osvaldo, Cacopardo, Ludovica , Ceron, Rachel, Contessa, Antonio, Giorgio, Roberto De, Diamanti, Antonella , Faticato, Maria Grazia, Hashmi, Sohaib K., Huizinga, Jan D. , Kapur, Raj P. , Lambe, Cécile, Lancon, Laurence, McManigal, Ryan, Palmitelli, Alessandro, Perreaux, Victor , Pitto, Michela, Proietti, Elisa, Rendu, John , Rybak, Anna, Sardar, Sabah , Stanghellini, V, Tambucci, Renato , Berghe, Pieter Vanden , Wang, Qianqian, Wangler, Michael, Wolfson, Sharon, Zada, Almira , Cacopardo, Ludovica , Perreaux, Victor , Pitto, Michela , Sanders, Kenton M , Vanden Berghe, Pieter , Wolfson, Sharon , Zada, Almira , Viti, Federica , Ceccherini, Isabella , Heuckeroth, Robert O. , Beyder, Arthur , Borrelli, Osvaldo , Ceron, Rachel H. , Chen, Jihong , Chiappori, Federica , Giorgio, Roberto De , Faure, Sandrine, Lambe, Cécile , Mousa, Hayat M. , Prato, Alessio Pini , PROIETTI, ELISA, Rybak, Anna , Thapar, Nikhil , Vassalli, Massimo , Wangler, Michael F , Zhou, Jiliang

Mayo Clinic

Neurogastroenterology & Motility | April 15, 2026 | Volume: 38 | Issue: 4 | Pages: No page available

10.1111/nmo.70317 | PMID 41981708 Get It

ABSTRACT Background Visceral myopathy (VSCM) is an ultra‐rare life‐threatening condition characterized by severe impairment of gastrointestinal (GI), genitourinary, and uterine smooth muscle. This disorder represents a significant clinical challenge due to variable presentation and the lack of standardized diagnostic and therapeutic protocols. Methods To discuss advances in the field, scientists and clinicians with a special interest in VSCM met in Arenzano, Genova, Italy in October 2024 for the second International Forum on Visceral Myopathy 2024 (IFVM2024) ( https://ifvm2024.ge.ibf.cnr.it/ ). Key Results As in the previous edition of the event ( https://poic‐e‐dintorni.org/efvm‐2022/ ), attendees included clinicians and researchers from around the world who study this disease, representatives from support organizations, patients affected by VSCM and their families, and companies that co‐funded the event. The present manuscript aims to summarize knowledge shared during the IFVM2024 conference, thus providing an updated state‐of‐the‐art summary of VSCM biology and disease management. Conclusions Here, we pay particular attention to the epidemiology of the disease, histopathology, genetics, novel treatments, advances in molecular and cell biology, experimental models, and the lived experiences and impact of this disorder on families.
FXR and BET signaling orchestrate to protect β cells
Cayabyab, Fritz , Tipirneni, Jalan, Chen, David, Choi, Jinhyuk, Hamba, Yu , Pham, Nhi, Tacto, Clarissa , Wu, Jie, Wang, Liu , Gershon, Paul D. , Perez, Harvey, Kim, Kiyoka, Shaheen, Ameen, Ipp, Eli , Wei, Zong, YOSHIHARA, Eiji, Wu, Jie , Mirzakhanyan, Yeva , Harada, Naoki , Fang, Sungsoon , Chen, Lin‐Feng

Mayo Clinic

No container title available | April 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.10.716420 | PMID 42039610 Get It

Abstract In both type 1 and type 2 diabetes (T1D and T2D), insulin-producing β cells undergo progressive dysfunction due to inflammation, leading to impaired glucose responsiveness, dedifferentiation, and cell loss. While bile acid (BA) dysregulation under diabetic conditions is known to influence metabolic and inflammatory pathways, its mechanistic role in β cell regulation remains incompletely defined 1–3 . Here we show that bile acid sensor Farnesoid X receptor (FXR) and Bromodomain and Extra-Terminal motif (BET) signaling cooperatively regulates β cell inflammatory response and β cell identity. We identified the physiological protein-protein interaction between FXR and the bromodomain-containing protein 4 (BRD4) as a regulatory axis that protects against β cell dysfunction. We show that FXR activation by Fexaramine (Fex) together with BRD4 inhibition by JQ1 synergistically suppressed IL-1β-induced inflammation while also improving β cell identity and insulin secretion in both db/db model and high-fat diet (HFD) plus multi low-dose streptozotocin (MLD-STZ) model of diabetes. Importantly, this cooperative effect is abolished in β cell–specific FXR knockout (βFXRKO) mice, establishing that FXR is required for the functional synergy between these pathways in vivo . Mechanistically, structure-guided modeling and mutational analyses identified a direct interaction between FXR and the BD2 domain of BRD4, depending on specific lysine acetylation sites. Additionally, inhibition of the BD2 domain of BET combined with FXR activation markedly improved β cell survival in human T1D and T2D models established from human pluripotent stem cell (hPSC)-derived islet-like organoids (HILOs). Collectively, these findings establish a BA–bromodomain axis as a transcriptional interface linking metabolic signaling and chromatin regulation, and highlight FXR–BET targeting as a promising strategy to counter progressive β cell failure in diabetes.
Automated Imaging Differentiation for Dementia
Chen, Robin , Chiu, Shannon , DeSimone, Jesse C. , Barmpoutis, Angelos , McMillan, Corey T. , Radhakrishnan, Hamsanandini , Irwin, David J. , Clark, Lyles , Vaillancourt, David E. , Irwin, David J , McMillan, Corey T , Wang, Wei , Kantarci, Kejal , Boeve, Bradley F.

Mayo Clinic

Neurology Open Access | April 13, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1212/wn9.0000000000000093 Get It

Analysis of MOG-IgG and AQP4-IgG Serology, Demographics, and Seasonality From Large Neuroimmunology Laboratory Registry and Clinical Cohorts
Vorasoot, Nisa , Edmond, Matthew C., Jenkins, Sarah M. , Cacciaguerra, Laura , Majed, Masoud , Kunchok, Amy , Chen, John J. , Rattanathamsakul, Natthapon , Tillema, Jan-Mendelt , Fryer, James P., Mills, John R. , Pittock, Sean J , Chen, John J , Cacciaguerra, Laura , Vorasoot, Nisa , Rattanathamsakul, Natthapon , Tillema, Jan‐Mendelt , Irani, Sarosh R. , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Neurology Open Access | April 13, 2026 | Volume: 2 | Issue: 2 | Pages: No page available

10.1212/wn9.0000000000000085 | PMID 42005425 Get It

Transcriptional and spatial profiling of fibroblasts from human lungs highlights CTHRC1+ cells as fibrogenic signaling hubs in fibrosis
Vanegas-Avendano, Natalia Del Pilar, Ghobashi, Ahmed, Sen, Chandani , Reader, Brenda F. , Gomperts, Brigitte N. , Ma, Qin, Tschumperlin, Daniel J. , Rojas, M. Montelongo, Vanegas-Avendaño, Natalia, Chen, H., Wellmerling, Jack , Rodriguez-Lopez, Jhonny , Ghobashi, Ahmed, Peters, Victor , Shilo, Konstantin , Mora, Ana Lucia , Rojas, Mauricio M.

Mayo Clinic

No container title available | April 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.04.08.717092 | PMID 41993306 Get It

Abstract Lung fibroblasts are key regulators of tissue homeostasis and extracellular matrix (ECM) remodeling, and their aberrant activation drives the progressive parenchymal scarring characteristic of idiopathic pulmonary fibrosis (IPF), a fatal disease with limited therapeutic options. Despite their central pathogenic role, lung fibroblasts are difficult to isolate due to their embedded position within the ECM, and standard in vitro culture conditions may lead to the loss of their native functional and transcriptional characteristics, hampering the study of fibroblast behavior in disease. The transcriptional heterogeneity of lung fibroblast subtypes and the extent to which culture-induced alterations diverge from native tissue signatures remain poorly understood. Here, we integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of lung tissue from IPF patients and age-matched healthy donors with transcriptomic profiling of cultured fibroblasts collected at passages 1 and 6 after isolation using three optimized protocols: whole lung cell suspension (WLCS), negative fraction enrichment, and outgrowth. Tissue-based analysis identified six transcriptionally distinct mesenchymal subtypes: alveolar, adventitial, inflammatory, peribronchial, CTHRC1+ and smooth muscle cell (SMC). The fibroblast subtype CTHRC1+ represented the most transcriptionally activated pro-fibrotic subtype, showing the greatest upregulation of ECM biosynthesis genes, a prominent role in intercellular communication, and preferential enrichment within fibroblastic foci in IPF lung tissue. Pseudotime trajectory analysis supported a directional transcriptional continuum from alveolar and inflammatory fibroblasts toward the CTHRC1+ state, driven by coordinated activation of pro-fibrotic transcription factors, including RUNX2, CREB3L1, and SCX. In vitro culture progressively reshaped fibroblast transcriptional identity relative to native tissue, with increased collagen and matrix metalloproteinase (MMP) expression during passaging, loss of distinct CTHRC1+ fibroblasts, and gain of alveolar fibroblasts displaying pro-fibrotic activation across all isolation protocols. These findings provide a high-resolution transcriptional map of lung fibroblast heterogeneity in IPF and highlight critical limitations of standard in vitro culture systems for recapitulating native fibroblast diversity, with important implications for the development and evaluation of fibroblast-targeted therapeutic strategies in IPF.
Educating Anesthesiology Residents and Their Support Persons to Improve Understanding and Increase Wellness: A Multisite Study
Martinelli, Susan M. , Tran, Thanh N. , Canter, Courtney , Hu, Di , Isaak, Robert S., Mulaikal, Teresa A., Ladlie, Beth L., Jain, Ankit , Willie, Chelsea, Stahl, David, Carter, Tekuila R., Zisblatt, Lara , Hoefnagel, A. L. , Marshall, Julie , Collins, Stephen, Martin, TD, Stahl, David L. , Ladlie, Beth, Carter, Tekuila R , Marshall, Julie M , Isaak, Robert S. , Afroze, Farzana, Jain, Ankit, Keneally, Ryan J. , Chen, Fengqian

Mayo Clinic

Anesthesia & Analgesia | April 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1213/ane.0000000000008030 | PMID 41962000 Get It

BACKGROUND: Burnout remains prevalent among anesthesiology residents. Contributing workplace factors include limited control over scheduling, unpredictable hours, critical patient care needs, and other residency challenges. The Family Anesthesia Experience (FAX) is a program designed to educate residents and their support persons on wellness and residency demands. The focus of this multisite study was to evaluate the impact of FAX on first year clinical anesthesiology (CA1, ie, PGY2s) residents’ wellness. METHODS: This was a prospective evaluation study involving 15 US anesthesiology residency programs, 13 of which completed FAX. CA1 wellness was evaluated through surveys assessing perceived stress as the primary outcome, with exploratory outcomes including burnout, depression, psychological wellness, and social support. Additionally, changes in support persons’ understanding and knowledge of residency demands were tracked over time. The study included a historical control group of 302 CA1s (2019-2021) who did not participate in FAX, and an intervention group of 88 CA1s that participated in FAX (2021-2022). Statistical analyses compared changes in metrics between groups using linear mixed models and generalized linear models. RESULTS: Significant reductions in perceived stress were observed in the intervention group at 6 months post-FAX (mean change = –2.14, 95% CI, –3.95 to –0.34; P = .021, effect size = 0.58) relative to the control group, but there was no sustained difference at 12 months. Compared to the control support persons, intervention support persons reported increased understanding of residency demands, with significant improvements at 6 (mean change = 2.80, 95% CI, 1.12–4.48; P = .001, effect size = 0.77) and 12 (mean change = 2.59, 95% CI, 0.12–5.05; P = .039, effect size = 0.71) months. Improvement in support persons’ understanding did not predict changes in CA1 wellness outcomes. First generation physician residents reported lower family support at baseline but showed significant improvements in family support at 6 months (mean change = 3.05 points; 95% CI, 0.25–5.84; P = .033; effect size = 1.23) compared to their non first generation peers. CONCLUSIONS: FAX participation was associated with reduced perceived stress in residents up to 6 months post-intervention. First generation physicians experienced greater improvements in perceived family support compared to their non first generation peers. Our findings suggest that resident wellness may be enhanced by engaging both residents and their support persons in an educational wellness program that outlines the professional expectations and demands of anesthesiology residency training.
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
Lim, Kenneth J C , Lee, Hee Eun , Chen, Zongming Eric, Bledsoe, Adam C. , Parrondo, Ricardo , Chhabra, Saurabh , Dooley, Katharine , Corraes, Andre De Menezes Silva , Gertz, Morie A. , Hwa, Y., Stephens, Haily, Kapoor, Prashant , Tan, Melinda S.Y., Kourelis, Taxiarchis , Warsame, Rahma , Yadav, Udit , Wiedmeier-Nutor, Julia Erin, Geyer, Susan, Kumar, Shaji , Chowla, Navreet , Lin, Y., Bledsoe, Adam C , De Menezes Silva Corraes, Andre , Gertz, Morie A , Hwa, Lisa, Cook, Joselle M , Binder, Moritz , Bergsagel, P. Leif , Yadav, Udit , Wiedmeier-Nutor, Erin, Fonseca, Rafael , Kumar, Shaji K , Chowla, Navreet , Parrondo, Ricardo D , Chhabra, Saurabh , Lim, Kenneth J C , Stephens, H. J. B., Cook, Joselle , Binder, Moritz , Bergsagel, P. Leif , Geyer, Susan M. , Ailawadhi, Sikander , Fonseca, Rafaël

Mayo Clinic

Blood Advances | April 10, 2026 | Volume: 10 | Issue: 13 | Pages: 4495-4507

10.1182/bloodadvances.2025018853 | PMID 41961998 Get It

Abstract Immune effector cell–associated enterocolitis (IEC-EC) has been observed after ciltacabtagene autoleucel (cilta-cel [Carvykti]) chimeric antigen receptor T-cell (CAR-T) therapy. It is associated with dismal outcomes and is poorly characterized. Here, we examined its clinical features, risk factors, and proposed management strategies. Among the 229 consecutive patients who received cilta-cel at Mayo Clinic, 9 (3.9%) presented with a nonresolving, nonbloody, grade 3 diarrhea, often requiring prolonged total parenteral nutrition. Gastrointestinal coinfections were seen in most patients. Median time from CAR-T infusion to symptom onset was 85 days (range, 35-166), and there appeared to be a latency from symptom onset to endoscopic evaluation. Histopathology findings resembling a graft-versus-host disease pattern of mucosal injury were most seen on duodenal biopsies, whereas 2 cases had patterns akin to a T-cell lymphoproliferative disorder (1 CD4+ and 1 CD8+). Independent associated factors for IEC-EC included high-risk disease as defined by the International Myeloma Society and International Myeloma Working Group, prolonged cytokine release syndrome, and antecedent delayed neurotoxicity. Response to first-line therapy comprising IV or oral corticosteroids, bile acid sequestrants, IV immunoglobulin, and antimicrobial-directed therapy was poor, with no durable responses. Biologic therapy appeared to induce durable responses in 3 of the 5 patients (2/2 vedolizumab; 1/3 infliximab); none of the responders had gastrointestinal coinfection. Early gastroenterology input for endoscopic evaluation with the inclusion of duodenal biopsy is a key component for diagnosis. Early institution of biologic therapy after failure of a short course of corticosteroids should be considered.